Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taoqishengxue is a Traditional Chinese Medicine (TCM) formulation, typically administered in capsule form, developed by Shanxi Hao Qijun Pharmaceutical in collaboration with Dongzhimen Hospital. It is primarily indicated for the treatment of cancer-related anemia and fatigue symptoms, often serving as an adjuvant therapy for patients undergoing chemotherapy. The formulation is designed according to TCM principles to tonify Qi and nourish blood, thereby stimulating hematopoietic function and alleviating systemic exhaustion. Clinical trials, such as ChiCTR1800020244, have evaluated its efficacy in improving hemoglobin levels and reducing fatigue in oncology patients when combined with standard Western medical treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taoqishengxue.